Clinical performance of the Solana® Point-of-Care Trichomonas Assay from clinician-collected vaginal swabs and urine specimens from symptomatic and asymptomatic women
Authors:
- 29 January 2017
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 17 (3) , 303-306
Abstract
Background: Solana® (Quidel) is a new rapid (Trichomonas vaginalis (TV) DNA. The assay has two steps: 1) specimen preparation, and 2) amplification and detection using isothermal Helicase-Dependent Amplification (HDA). The objective was to demonstrate the performance of Solana for vaginal swabs and female urines based on comparison to wet mount and TV culture. Performance was also compared to the Aptima-TV assay. Methods: Urine and four clinician-collected vaginal swabs were collected. The first two were used for FDA composite reference (wet mount; InPouch TV Culture). The third swab was used for Solana. Sensitivity/specificity were based on the reference method. A specimen was considered positive if either test was positive. The fourth swab was for Aptima-TV. Results: Vaginal swabs and urines were obtained from 501 asymptomatic and 543 symptomatic women. Prevalence of TV by was 11.5%. For swabs, Solana® demonstrated high sensitivity and specificity from asymptomatic (100%/98.9%) and symptomatic (98.6%/98.5%) women, as well as for urines from asymptomatic (98.0%/98.4%) and symptomatic (92.9%/97.9%) women, compared to the reference method. Compared to Aptima-TV, the sensitivity/specificity was 89.7%/99.0% for swabs and 100%/98.9% for urines. Conclusion: The Solana® assay performed well compared to the reference assays.Keywords
Funding Information
- National Institute of Biomedical Imaging and Bioengineering (Quidel Corporation, Athens, Ohio, U-01068613, NIH, NIAID, U54EB007958, NIBIB)
This publication has 25 references indexed in Scilit:
- Trichomoniasis and HIV interactions: a reviewSexually Transmitted Infections, 2013
- Prevalence of Trichomonas vaginalis and Coinfection with Chlamydia trachomatis and Neisseria gonorrhoeae in the United States as Determined by the Aptima Trichomonas vaginalis Nucleic Acid Amplification AssayJournal of Clinical Microbiology, 2012
- Global incidence and prevalence of selected curable sexually transmitted infections: 2008Reproductive Health Matters, 2012
- Determinants of Per-Coital-Act HIV-1 Infectivity Among African HIV-1–Serodiscordant CouplesThe Journal of Infectious Diseases, 2012
- Molecular Testing for Trichomonas vaginalis in Women: Results from a Prospective U.S. Clinical TrialJournal of Clinical Microbiology, 2011
- Trichomoniasis and Other Sexually Transmitted Infections: Results From the 2001–2004 National Health and Nutrition Examination SurveysSexually Transmitted Diseases, 2009
- Prospective Study of Trichomonas vaginalis Infection and Prostate Cancer Incidence and Mortality: Physicians' Health StudyJNCI: Journal of the National Cancer Institute, 2009
- Trichomonas vaginalisInfection and Human Immunodeficiency Virus Acquisition in African WomenThe Journal of Infectious Diseases, 2008
- Rapid Antigen Testing Compares Favorably with Transcription-Mediated Amplification Assay for the Detection of Trichomonas vaginalis in Young WomenClinical Infectious Diseases, 2007
- Trichomonas vaginalis Associated With Low Birth Weight and Preterm DeliverySexually Transmitted Diseases, 1997